原発性胆汁性肝硬変におけるアフェレシス治療(<特集>肝・膵疾患とアフェレシス)

概要

論文の詳細を見る
Recently several drug therapies considered effective to treat patients with primary biliary cirrhosis(PBC)have often been ineffective. The patients report gradually more severe general fatigue and itching. Currently the most effective therapy for PBC is liver transplantation; however, since it is difficult to receive this procedure in Japan, we have performed and are performing extracorporeal circulation therapy as a bridging therapy until a liver transplantation can be done. The six-month death rate for the logistic analysis and total bilirubin concentration of patient#1 was already 82%and 10.5mg/dl, respectively. However, the patient's condition had been stable for about 6 years after the initiation of double-filtration plasmapheresis. The death rate of patient#2 remained 15% for 8 years with it. Her high concentration of anti-mitochondrial antibody(AMA)and AM_2A became negative about 5 years after the initiation of double-filtration plasmapheresis. The removal rate for bilirubin is not good by double-filtration plasmapheresis though this therapy once a month has been effective to keep patients in good condition. This suggests that the therapy may have an immune modulation function for PBC patients. In the future, study of the immune modulating effect of membrane material will be important.
日本アフェレシス学会の論文
1997-10-31